Small-molecule α-lipoic acid targets ELK1 to balance human neutrophil and erythrocyte differentiation

Yimeng Zhang, Ya Zhou, Xiaohong Li, Pan Xu, Ju Bai, Yijin Chen, Zhenyang Lai, Qiang Chen, Feng Ma, Yong DongStem 2024 · DOI

Abstract: ALA and ELK1 are found to regulate both human granulopoiesis and erythropoiesis via RNA spliceosome, and ALA-ELK1 signal might be the target of human leukemia therapy.

Introduction

In the complex process of hematopoiesis, hematopoietic stem progenitor cells (HSPCs) must decide whether to differentiate into oxygen-carrying erythrocytes (red blood cells) or infection-fighting myeloid cells like neutrophils. In hematological malignancies such as Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), this delicate balance is often destroyed, leading to an overproduction of dysfunctional myeloid cells and a severe deficiency of red blood cells, resulting in anemia. While the primary drivers of these lineages are known, the molecular switches that co-regulate both sides of this balance remain poorly understood. This study investigates how $\alpha$-lipoic acid (ALA) and the transcription factor ELK1 act as critical regulators of this lineage decision.

Methodology

To investigate the regulatory mechanisms of blood cell differentiation, the researchers employed a multi-faceted approach:

  • Human Cell Models: $CD34^+$ HSPCs were isolated from human cord blood and cultured in specific cytokine environments to induce erythroid or myeloid differentiation.
  • Genetic Perturbation: Lentiviral vectors were used to overexpress or knock down specific isoforms of ELK1 (L-ELK1 and S-ELK1) and the splicing factor SRSF11.
  • In Vivo Validation: Human HSPCs were transplanted into immunodeficient NSG mice to study differentiation in a physiological context. Additionally, a conditional overexpression mouse model ($Elk1^{LSL/+}Mx1$-$Cre$) was utilized to validate findings in a native environment.
  • Molecular Analysis: The team performed bulk RNA-sequencing (RNA-seq) and mass spectrometry to identify downstream gene networks and protein-protein interactions. Publicly available datasets were used to correlate findings with clinical AML subclasses.

Key Insights: The ALA-SRSF11-ELK1 Axis

The study identified ELK1 as a potent negative regulator of the erythroid lineage. While ELK1 promotes neutrophil formation, its presence effectively "blocks" cells from becoming red blood cells.

The researchers discovered that ALA functions by modulating the RNA splicing of ELK1. ALA treatment upregulates the splicing factor SRSF11, which binds to ELK1 mRNA and suppresses the production of the long isoform (L-ELK1). L-ELK1 was found to be a significantly more powerful regulator than the short isoform (S-ELK1), strongly upregulating genes associated with neutrophil activity and interfering with hypoxia signaling pathways (e.g., VEGFA, BNIP3, and PDK1) necessary for erythropoiesis.

Results: Shifting the Differentiation Balance

Experimental results demonstrated that ALA treatment significantly shifts the differentiation landscape. In in vitro cultures, ALA treatment more than doubled the production of $CD71^+ GPA^+$ erythrocytes compared to controls (28.5% vs. 11.9%).

ALA treatment promotes erythroid differentiation while inhibiting myeloid lineages in human HSPCs.

Further in vivo experiments showed that overexpressing Elk1 in mice led to a massive expansion of myeloid progenitors (GMPs) and mature neutrophils, while simultaneously depleting erythroid progenitors (MEPs) and mature red blood cells. This phenotype mimics the clinical presentation of AML, where ELK1 is often found to be significantly overexpressed. Interestingly, knocking down ELK1 did not significantly boost red cell production beyond baseline, suggesting that ELK1 acts primarily as a "brake" that is activated during disease states rather than a primary driver of normal development.

Conclusion and Future Directions

The identification of the ALA-SRSF11-ELK1 axis provides a potential therapeutic target for treating leukemia-associated anemia. By "releasing the brake" held by ELK1, it may be possible to simultaneously inhibit leukemic myeloid expansion and rescue red blood cell production.

However, several challenges remain for clinical application. ALA is rapidly metabolized, which may limit its efficacy as a standalone treatment. Future work will need to explore more stable delivery methods or direct genetic targeting of ELK1. Additionally, the precise molecular interactions between ELK1 and core erythroid transcription factors like GATA1 require further elucidation to fully understand the regulatory landscape of human hematopoiesis.

Summary updated

Abstract

ALA and ELK1 are found to regulate both human granulopoiesis and erythropoiesis via RNA spliceosome, and ALA-ELK1 signal might be the target of human leukemia therapy.
BibTeX
@inproceedings{zhang2024small,
  author = {Yimeng Zhang and Ya Zhou and Xiaohong Li and Pan Xu and Ju Bai and Yijin Chen and Zhenyang Lai and Qiang Chen and Feng Ma and Yong Dong},
  title = {{Small-molecule α-lipoic acid targets ELK1 to balance human neutrophil and erythrocyte differentiation}},
  booktitle = {Stem},
  year = {2024},
  doi = {10.1186/s13287-024-03711-6},
}
Figure